Single‐agent chemotherapy with romidepsin and a CD30‐antibody drug conjugate, brentuximab vedotin (BV), have shown lower response rates in R/R PTCL ranging from 25% to 41%.3 The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.